SS
MRNS

Steve Schonfeld’s Marinus Pharmaceuticals, Inc MRNS Stock Holding History

Steve Schonfeld’s Portfolio MRNS Stock Details MRNS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-67,698
Closed -$119K – 2520
2024
Q3 		$119K Buy
67,698
+37,598
+125% +$52.5K ﹤0.01% 1858
2024
Q2 		$35.2K Buy
+30,100
New +$75.3K ﹤0.01% 1969
2023
Q4 		– Sell
-253,412
Closed -$2.04M – 2327
2023
Q3 		$2.04M Buy
253,412
+103,935
+70% +$865K 0.02% 823
2023
Q2 		$1.62M Buy
149,477
+101,227
+210% +$867K 0.01% 817
2023
Q1 		$333K Buy
+48,250
New +$303K ﹤0.01% 1328
2018
Q4 		– Sell
-10,025
Closed -$401K – 1265
2018
Q3 		$401K Buy
+10,025
New +$285K 0.02% 625
2018
Q1 		– Sell
-52,972
Closed -$1.73M – 1014
2017
Q4 		$1.73M Sell
52,972
-16,327
-24% -$440K 0.14% 204
2017
Q3 		$1.63M Buy
+69,299
New +$777K 0.15% 176

Other funds holding MRNS

BCM
Beryl Capital Management Redondo Beach, California $111M AUM 205.39% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
OBAM
ODDO BHF Asset Management Paris, France $2.16B AUM 43.32% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Steve Schonfeld's MRNS Position: Q4 2024 in Review

Steve Schonfeld sold out of Marinus Pharmaceuticals, Inc (MRNS) in Q4 2024, closing a stake of 67,698 shares — an estimated $119K sold.

Steve Schonfeld first reported a position in MRNS in Q3 2017 and held it in 8 quarters. The position peaked at $2.04M in Q3 2023. 53 funds tracked by Wall St. Rank hold MRNS as of Q4 2024.

  • Steve Schonfeld reported no remaining Marinus Pharmaceuticals, Inc position as of Q4 2024 after selling out during the quarter.
  • Steve Schonfeld sold 67,698 Marinus Pharmaceuticals, Inc shares in Q4 2024, an estimated $119K.
  • Steve Schonfeld first reported a position in Marinus Pharmaceuticals, Inc in Q3 2017 and held it in 8 quarters.
  • Steve Schonfeld's Marinus Pharmaceuticals, Inc position peaked at $2.04M in Q3 2023.
  • 53 funds tracked by Wall St. Rank held Marinus Pharmaceuticals, Inc as of Q4 2024.

Based on Schonfeld Strategic Advisors's 13F filing for Q4 2024, filed 14 Feb 2025.